LB1410 study for advanced lung, colon, and other cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial tests LB1410, a new cancer treatment, to see if it is safe and may work for people with advanced cancers. It focuses on specific cancer types and requires certain prior treatments and lab test results.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older
- Have advanced or metastatic cancer (or lymphoma) for which standard treatment has failed, isn’t available, or isn’t suitable
- Match one of the study groups (examples: NSCLC after certain prior treatments, CRC with limited prior therapy, or other listed cancers with limited prior therapy)
- Have recent tumor tissue available for lab testing (for PD-L1 and TIM-3) or be able to provide it during screening
- Be well enough to participate: performance status 0–1, life expectancy at least 12 weeks, and at least one measurable tumor spot
- Have adequate blood counts and organ function on recent blood tests (done within 7 days of starting)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two experimental drugs (LB1410 and LB4330) in people with advanced or metastatic solid tumors that have stopped responding to standard treatments or where no standard treatment exists. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.
This trial tests a new combination treatment (BL-B01D1 plus a PD-1 inhibitor) for people with advanced lung cancer or nasopharyngeal cancer. It aims to see if the combination is safe and effective for patients whose cancer has not responded to earlier treatments.
This study tests a new drug, ILB-3101, for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how well it works.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug, LM-2417, for people with advanced solid tumors that have come back or not responded to treatment. The study will see if LM-2417 is safe and effective, possibly as a new option for those who have run out of standard therapies.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.